# Vicarious Surgical Inc.: Form 10-Q for the period ended Sep 30, 2022

- Company: [Vicarious Surgical Inc.](/companies/rbot.md) (CIK 1812173)
- Form: 10-Q
- Filed: 2022-11-07
- Accepted by EDGAR: Nov 7, 2022, 17:12 ET
- Period: 2022-09-30
- Accession: 0001213900-22-069803
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1812173/000121390022069803/f10q0922_vicarioussurg.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1812173/000121390022069803/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2022-07-01 to 2022-09-30 | $12.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-01-01 to 2022-09-30 | $32.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-07-01 to 2022-09-30 | −$22.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-01-01 to 2022-09-30 | −$59.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-07-01 to 2022-09-30 | $31.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2022-01-01 to 2022-09-30 | $89.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | −$24.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | $16.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | −$0.20 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | $0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | −$0.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | $0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 121,965,277 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 121,201,693 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | −$42.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2022-09-30 | $126.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $131.3m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $150.7m | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $11.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $41.7m | us-gaap:Liabilities |
| Long-term debt | at 2022-09-30 | $250.0k | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2022-09-30 | $109.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1812173/000121390022069803/f10q0922_vicarioussurg.htm

Filed Nov 7, 2022.
Source: SEC EDGAR, the filing index for accession 0001213900-22-069803. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.
